Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568683 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02568683 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 10 participants.
The verdict
NCT02568683, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.
Interventions
- DRUG Vincristine
- DRUG Entospletinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02-11 |
| Est. Completion | 2017-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568683
The ClinicalTrials.gov registry entry for NCT02568683 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vincristine is the first listed.
NCT02568683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02568683 about?
NCT02568683 is a clinical study titled "Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)". The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.
What is the current status of trial NCT02568683?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-02-11. Estimated completion is 2017-06-22.
What interventions are being tested in trial NCT02568683?
The interventions under investigation include: Vincristine (DRUG), Entospletinib (DRUG).
Who is sponsoring clinical trial NCT02568683?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.